Rossari Biotech posts 11% revenue growth in Q1 FY26; profit before tax dips slightly as input costs and expenses surge.

• Revenue rose to ₹543.72 crore; EBITDA grew 4.6% but the margin slipped to 12.5% due to rising input costs.
• HPPC and AHN divisions led growth with 16% and 12% increases; exports were lower QoQ but grew YoY.
• Capacity expansions are underway across segments to boost output, agility, and value in high-growth sectors like personal care and agrochem.